{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-017655","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2023-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.504893+00:00","generated_at":"2026-06-08T20:28:13.435031+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris Q3 net loss $29.3M, revenue $9.3M; zunsemetinib RA data due Nov 2023","bullets":["Net loss of $29.3M for Q3 2023 compared to $20.0M in Q3 2022.","Total revenue $9.3M, down from $19.0M due to prior year Lilly payment.","Cash and securities $187.0M as of Sept 30, 2023; sufficient through end of 2025.","Zunsemetinib Phase 2b RA topline data expected November 2023.","ATI-1777 Phase 2b AD data expected around year-end 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-017655","json":"https://secwatch.observer/filing/0001558370-23-017655.json","markdown":"https://secwatch.observer/filing/0001558370-23-017655.md","text":"https://secwatch.observer/filing/0001558370-23-017655.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023017655/0001558370-23-017655-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023017655/acrs-20231106x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T20:28:13.435031+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"921033fff8c4305aab547e0bbcf0d3c41f5170f5","claim":"Aclaris Therapeutics, Inc. reported third quarter of 2023 results: revenue $9.3 million, net income net loss was $29.3 million.","evidence_excerpt":"Results ​ Third Quarter 2023 ​ ● Net loss was $29.3 million for the third quarter of 2023 compared to $20.0 million for the third quarter of 2022. ​ ● Total revenue was $9.3 million for the third quarter of 2023 compared to $19.0 million for the third quarter of 2022. The decrease was primarily driven by a one-time upfront payment under the non- ​ ​","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023017655/0001558370-23-017655-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter of 2023"},{"label":"Revenue","value":"$9.3 million"},{"label":"Net income","value":"net loss was $29.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}